InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) Recovers Some Ground

Yesterday, InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) finally managed to turn the tide, adding 12.24% to its market value after a protracted red run.

As previously discussed, NVIV‘s fall from the high it had achieved when it skyrocketed on Nov. 12 was all but inevitable – $1.4 per share is just too high of a price for the stock of a company in NVIV‘s stage. It was only natural that the price dropped, although admittedly it did take quite a long time to do so.

Still, the OTC Markets being a place of both hype and opportunism, many people saw NVIV‘s latest dip as a cue to jump on its stock. This may not have been a bad strategy, because NVIV is currently widely regarded as one of the more stable companies on this particular exchange.

Its financials look decent, its share structure is good, and it doesn’t seem prone to toxic funding, which is the bane of investor value for pharmaceutical companies.

Unfortunately, the fact that the company is slowly but surely creeping towards commercial success is no guarantee that its stock prices will be following the same steady ascending pattern. More often than not, hype, volatility and opportunism determines an OTC Markets ticker’s movements.

This is pretty much the reason why NVIV stock prices are as unstable as they are, even though the company looks solid.